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ABSTRACT
Background. CD4 cell count in adults with human immunodeficiency virus (HIV)
infection (PLHIV) not receiving antiretroviral therapy (ART) influences tuberculosis
(TB) risk. Despite widespread use in models informing resource allocation, this
relationship has not been systematically reviewed.
Methods. We systematically searched MEDLINE, Aidsinfo, Cochrane review database
and Google Scholar for reports in English describing TB incidence stratified by
updated CD4 cell count in cohorts of HIV-positive adults (age ≥15 years) not on
ART (PROSPERO protocol no: CRD42016048888). Among inclusion criteria were:
reporting precision for TB incidence, repeated CD4 measurements, and TB incidence
reported for those not on ART or monotherapy. Study quality was assessed via the
Newcastle-Ottawa tool for cohort studies. A Bayesian hierarchical model was fitted
to estimate the pooled factor increase in TB incidence with respect to CD4 cell count
decrement.
Results. A total of 1,555 distinct records were identified fromwhich 164 full text articles
were obtained. Common reasons for exclusion of full texts were: no valid TB incidence,
no repeat CD4measurements, and not reporting TB incidence by ART status. The seven
studies included reported on 1,206 TB cases among 41,271 individuals, with a typical
median follow-upof four years. Studieswere generally rated asmoderate or high quality.
Our meta-analysis estimated a 1.43 (95% credible interval: 1.16–1.88)-fold increase in
TB incidence per 100 cells per mm3 decrease in CD4 cell count.
Discussion. Our analysis confirms previous estimates of exponential increase in TB
incidence with declining CD4 cell count in adults, emphasizing the importance of early
ART initiation to reduce TB risk in PLHIV.
Subjects Epidemiology, Global Health, HIV, Infectious Diseases, Statistics
Keywords TB, Antiretroviral therapy, Modeling, Opportunistic infections, CD4 cell count
INTRODUCTION
Tuberculosis (TB) and the human immunodeficiency virus (HIV) are the two leading
infectious killers with an estimated 1.4 million deaths from TB (excluding those with HIV)
and 0.4 million deaths in those with HIV and TB in 2015 (World Health Organization,
2016). HIV is the most potent known risk factor for TB disease incidence and has been a
major factor in the upswing in TB incidence in sub-Saharan Africa throughout the 1990s.
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Around 11% of the 10.4 million incident TB cases globally and around 20% of total global
mortality from TB were estimated to be in people living with HIV (PLHIV) in 2015 (World
Health Organization, 2016). TB is implicated in 36% of deaths from HIV (UNAIDS, 2016).
Anti-retroviral therapy (ART) for in PLHIV is known to be around 70% protective
against TB incidence (Suthar et al., 2012). Isoniazid preventive therapy (IPT) against
TB is now recommended for 36 months in PLHIV (World Health Organization, 2015b),
and further reduces the risk of TB by 30–50% (Golub et al., 2007; Rangaka et al., 2014;
Samandari et al., 2011; Yirdaw et al., 2014). ART additionally has substantial benefits of
reduced all-cause mortality (Antiretroviral Therapy Cohort Collaboration, 2008). Despite
encouraging recent progress however, under 50% of adults living with HIV are on ART
(UNAIDS, 2016), and under 40% of PLHIV newly enrolled in care received IPT in 2015
(World Health Organization, 2016).
CD4+ cells play a pivotal role in both HIV and Mycobacterium tuberculosis (M.tb)
infection, and the peripheral blood CD4+ lymphocyte count (CD4 cell count) played
an important role historically in ART initiation guidelines and has been shown to be a
strong predictor of TB risk. Despite the fact that HIV treatment guidelines recommend
ART initiation of regardless of CD4 count (World Health Organization, 2015a), individuals
have typically undergone some CD4 decline by the time they are diagnosed and begin
HIV treatment. Understanding the population-level implications of this increase in mean
risk of TB is therefore still crucial to understanding the epidemiology of a given setting,
predicting the impact of interventions to improve HIV diagnosis, and resource planning.
Previous analyses (Williams & Dye, 2003; Williams et al., 2010) have found an exponential
relationship between CD4 decrement in PLHIV not on ART and TB disease incidence,
and their analysis has been widely used since in modeling analyses of the impact of
HIV interventions on TB, linked HIV/TB resource planning (e.g., the OneHealth Tool
frequently used to support applications to the Global Fund), and is used in TB burden
estimation (Pretorius et al., 2014a; Pretorius et al., 2014b;Williams & Dye, 2003;Williams et
al., 2010). However, this relationship was not based on a transparent systematic review of
available data.
Given the importance of the quantitative correspondence between CD4 count and TB
risk in PLHIV not on ART and the absence of a systematic evidence synthesis, we sought
to provide a meta-analytic estimate of this relation for adults based on systematically
identified cohorts of ART-naïve PLHIV reporting TB incidence by updated CD4 count.
METHODS
This systematic review is reported in accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analyses (PRISMA) (Moher et al., 2009). The protocol was
registered with the International Prospective Register of Systematic Reviews (identification
number: CRD42016048888).
Cohort definitions, selection criteria, and search strategy
We sought cohorts of HIV-positive adults (≥15 years of age) who were not on ART, with
HIV infections and data stratified by CD4 count (exposure) at TB incidence (outcome).
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Studies were also included if they reported relative measures of TB incidence across CD4
categories, such as hazard ratios. The analysis comparison was between TB incidences for
different CD4 count categories.
To be eligible, a study had to present empirical data on at least five cases of TB in adults.
Studies were excluded if they explicitly restricted to groups not generally representative of
adult TB cases in that population at that time, e.g., studies that only addressed one clinical
manifestation of TB; that only comprised of hospitalized TB cases; studies that focused
on migrant populations. Where explicit use of isoniazid preventive therapy was stated,
those receiving IPT were excluded (similarly for any other form of prophylaxis). To allow
appropriate study weighting, TB incidence or relative TB incidence had to be reported with
confidence intervals, or as person-time and the number of incident TB cases.
To be eligible, studies had to report separately on individuals not onART (ART including
monotherapy etc.). Studies where themajority ofHIV infections are known to be notHIV-1
were excluded. (HIV-1 is the most common major type of HIV.) We required at least one
CD4 count measurement subsequent to the baseline measurement at enrolment.
If the same cohort was published more than once, or individuals were described in more
than one cohort, studies were only included once.
We searched MEDLINE (11/16) for articles published in English at any time. (See
Appendix S1 for full search strategy.) The search was developed in consultation with an
information specialist and sensitivity assessed by checking against known papers from
Williams’ analyses (Williams & Dye, 2003; Williams et al., 2010). We also searched the
Aidsinfo database for registered studies that may have had relevant publications listed, and
the Cochrane database of systematic reviews for relevant reviews.
The references of included studies were also searched for additional studies, as were
articles listed as citing these articles on Google Scholar.
Data extraction and risk of bias
Two reviewers (PKE & WJM) independently screened articles returned by the search, and
discrepancies were resolved in discussion with a third reviewer (PJD). Reasons for rejection
were recorded.
A data extraction form was developed based on previous experience with a related
review (Dodd et al., 2017), and refined after application to the first included article. Data
was independently extracted (by PKE & WJM) on: first author, publication year, study
country, study years, study description, ethnicity, CD4 cell count category, number in
cohort, number of TB cases, crude and adjusted hazard ratios, patient years, TB incidence
(and 95% confidence interval [CI]), frequency of CD4 cell count measurement, proportion
of TB bacteriologically confirmed, Bacille Calmette Guérin (BCG) vaccination coverage,
tuberculin skin test (TST) status, age range, sex and HIV epidemic type. Any discrepancies
were resolved by discussion with a third reviewed (PJD).
The 95% Poisson exact confidence intervals based on reported event counts and person
time were used to define precision for incidence data points. Where only adjusted hazard
ratios with respect to a given CD4 category were reported, the stated 95% CIs were used
to estimate precision. For the single TB incidence data point with zero TB events, we used
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the lower bound of the Poisson exact confidence interval divided by 100 as the central
incidence estimate (as the logarithm of zero is not defined), and examined sensitivity to
this approximation by repeating our analysis with an incidence point estimate value 10
times smaller again. CD4 category mid-points were used in statistical analyses with the
assumption of an upper CD4 count of 1,000 cells/mm3 where not stated.
To assess risk of bias in individual studies, the Newcastle-Ottawa instrument for cohort
studies (Wells et al., 2000) was adapted (see Appendix S1) and summarized as low-,
moderate-, or high-quality for our question on selection, comparability and outcome
domains depending on whether few, some, or most of the question items in a domain were
answered positively.
Statistical analysis
In order to use information on both TB incidence and hazard ratios, we performed a
Bayesian hierarchical meta-analysis assuming that the logarithmic TB incidence for a given
CD4 category was proportional to a study-specific intercept (capturing the background TB
incidence rate) and a study-specific gradient with respect to CD4 cell count drawn from
a common distribution (analogously to a frequentist random-effects model). The model
was fitted with Markov chain Monte Carlo (MCMC) methods in the R environment for
statistical computing (R Core Team, 2016) using RStan (Stan Development Team, 2016)
(see details and code in Appendix S1). Gelman–Rubin convergence statistics computed
and chains plotted.
Heterogeneity was calculated as τ 2, the variance of the summary distribution for the
log-gradient, and a corresponding I 2 statistic evaluated using the summary statistic of
Higgins & Thompson (2002) for individual studies’ posterior variance. Forest plots of the
individual and summary gradients with respect to CD4 were produced, and a funnel plot
to assess risk of publication bias.
We computed the implied factor increase in TB incidence per 100 cell per mm3 by our
estimate, and similarly the incidence rate ratio for TB implied at different CD4 counts.
RESULTS
See Supplemental Information 3 for location of items reported.
Study selection and characteristics
Database searching returned 1,824 records, which together with 5 records identified by
other means, led after screening to the full texts of 150 articles being examined (see flow
diagram, Fig. 1). The most common reason for exclusion at the full text stage was TB
incidence not being reported (with an implied measure of precision); use of ART (or
monotherapy) in the cohort with TB incidence measures without stratified reporting by
ART status; and only CD4 at baseline beingmeasured. The studies used in previous analyses
(Williams & Dye, 2003; Williams et al., 2010) were captured by this strategy, but rejected
for only measuring CD4 at baseline or not reporting TB incidence in PLHIV not on ART.
Data from seven studies was finally extracted for meta-analysis.
The seven studies included are summarized in Table 1 (Assebe et al., 2015; Collins
et al., 2015; Grant et al., 2009; Markowitz et al., 1997; Monge et al., 2014; Nicholas et al.,
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Full text articles excluded 
(n=150) 
 
Hospitalised population (7) 
No measure of incidence (69) 
No. of study cases <5 (1) 
Article is a review (1) 
Not representative of general population (3) 
Only baseline CD4 taken (18) 
Only representative of one specific type of TB (6) 
Patient population aged <15 years (1) 
Patients taking IPT or other forms of prophylaxis (1) 
Patients on ART (including monotherapy) (17) 
TB incidence not reported by CD4 cell count (10) 
TB not primary outcome (3) 
TB prevalent at beginning of study (13) 
Records identified through 
database searching 
(n=1824) 
Additional records 
identified through other 
sources 
(n=5) 
Records after duplicates 
removed 
(n=1555) 
Records screened 
(n=1555) 
Records excluded 
(n=1398) 
Full text articles assessed 
for eligibility  
(n=157) 
Studies included for 
qualitative & quantitative 
synthesis 
(n=7) 
Figure 1 PRISMA flow diagram of review process.
Full-size DOI: 10.7717/peerj.4165/fig-1
2011; Wolday et al., 2003). Studies included reported on 1,206 TB cases among 41,271
individuals, with a median over median follow-up times of 4.0 years. Three studies were
based in sub-Saharan Africa (with heterosexual transmission predominating), one in Haiti,
and the rest in the US or Europe (mostly men-who-have-sex with men, or injecting drug
use), with most of the data being from the late 1990s or early 2000s. The more recent
studies included evaluations of ART timing and IPT. The largest study was a retrospective
observational cohort in the UK (Grant et al., 2009). Less than half the studies reported
(three of seven) TST status, with the proportion of patients in cohorts being TST positive
ranging between 6% and 38%. The proportion of TB bacteriologically confirmed (reported
by four of seven studies) ranged between 50% and 71%. Only one study (Wolday et al.,
2003) reported BCG vaccination status (38% of PLHIV).
Most studies (five of seven) reported person-time and incident TB cases by CD4 count;
the two that did not (Assebe et al., 2015; Collins et al., 2015) both reported adjusted hazard
ratios for CD4 categories derived from Cox proportional hazards models. In addition,
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Table 1 Summary of studies.
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<350 aHR= 3.16 (1.04–3.92)
350–499 aHR= 2.87 (1.37–6.03)Assebe,
2015
Ethiopia 2008–2012
Retrospective cohort study
of patients in pre-ART care
at a tertiary hospital focusing
on the effect of IPT. Cohort
comprised IPT (n= 294) and
non-IPT (n = 294) patients
sampled from 3,476 in pre-
ART care. Median follow-up
24.1 months. Adjusted hazard
ratio from Cox PH model
reported for CD4 categories
(adjusting for IPT use) based
on n= 585 patients.
IPT found to halve TB
incidence.
588 Black African
≥500
49 1297.5
aHR= 1g
– –
15–64 38 Heterosexual B/A/B
Collins,
2015
Haiti 2005–2012 Open-label RCT, using the
CIPRA-HT001 cohort to re-
ceive early ART (n = 408)
or delayed ART (i.e., when
CD4< 200; n= 408). Median
follow-up of 4.4 in the early
treatment arm and a median
3.9 years in the delayed treat-
ment arm. 43 participants
with prevalent TB at initiation
excluded from incidence anal-
ysis, which reported an ad-
justed HR of TB incidence per
50 cells/mm3 CD4 decrement
from Cox PH models (this in-
cluded person-time on ART).
Model including adjustments
for treatment group and PPD-
status/IPT used.
Delayed ART initiation
results in persistent in-
creased TB risk.
816 – – 96 aHR= 1.24 (1.11–1.38) per 50 CD4
cells/mm3 decline
61 27e ≥18
(40)
42 – B/A/A
<50 9 176 51.1
50–199 13 612 21.2
200–349 14 1,453 9.6
350–500 7 1,443 4.9
Black African
>500 7 1,553 4.5
≥16
(34) 36 Heterosexual
<50 9 850 10.6
50–199 25 2,631 9.5
200–349 20 6,636 3
350–500 9 7,548 1.2
White
>500 3 9,560 0.3
≥16
(35) 92 MSM
<50 3 252 11.9
50–199 4 535 7.5
200–349 5 1,422 3.5
350–500 11 1,587 6.9
Grant,
2009 UK 1996–2005
An observational cohort study
of patients (UK Collabora-
tive HIV Cohort, restricted
to those who joined prior to
2006); median follow-up 4.2
years. TB within 3 months
of enrolment excluded, as
were individuals without CD4
count or who were lost to
follow-up or died within 3
months of first visit. TB inci-
dence reported separated for
those not taking ART.
Early HIV diagnosis and
IPT key to reducing the
particularly high TB
incidence in non-white
& low-CD4 PLHIV in
the UK.
22,833
Other
>500 1 2,180 0.5
– –
≥16
(34) 77 MSM
A/B/B
(continued on next page)
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Table 1 (continued)
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<200 17 1,417 12Markowitz,
1997 USA 1988–1990
Prospective, multi-center co-
hort study of HIV seroposi-
tive patients (the Pulmonary
Complications of HIV Infec-
tion Study) representative of
US PLHIV; median follow-up
of 53 months. Around 4% of
patients were taking IPT. TB
incidence increased with PPD
induration.
TB incidence highest in
patients with CD4 <200
and PPD patients.
1,130 White/Black
/Hispanic ≥200 14 2,800 5
71 6d
18–67
(37b) 87
MSM/IDU
/hetero-
sexual
C/B/A
<200 124 aHR= 5.20(3.25–8.33)
200–350 32 aHR= 1.54(1.01–2.34)Monge,
2014
Spain 2004–2010
Open, multi-center, prospec-
tive cohort of ART naïve
patients (CoRIS= Span-
ish AIDS Research Network
Cohort). Around half of TB
cases were in people on ART.
Adjusted rate ratios by CD4
category from Poisson re-
gression (adjusting for ART-
status) were therefore used.
TB episodes during follow-up
and up to 3 months prior to
enrolment were included.
Early HIV diagnosis and
ART should be used to
help address high TB
incidence in PLHIV.
6,811 –
>350 37 aHR= 1g
65 – >13 80
Heterosexual
/IDU
B/A/C
<50 59 98 602
50–99 68 170 401
100–199 162 732 221
Nicholas,
2011
Guinea,
Kenya,
Malawi,
Mozam-
bique,
Nigeria &
Uganda
2006–2008
Multi-center, retrospective
cohort study based on the
FUCHIA database from all
sub-Saharan Médicins sans
Frontières HIV programmes.
TB at, or within 15 days of,
enrolment excluded; patients
with <15 days of follow-up
excluded. Median follow-up
9 months. TB recorded pre-
ART and during ART. Me-
dian pre-ART follow-up of 9
months.
Importance of early
HIV diagnosis and
treatment and imple-
mentation of the 3Is.
8,998 Black African
≥200 398 6,180 64
– – 27–40c
(33) 27 Heterosexual
A/A/B
<200 5 46 107.6
200–499 5 121 41.2Wolday,
2003
Ethiopia 1997–2001
A prospective cohort study
(Ethio-Netherlands AIDS Re-
search Project= ENARP) to
study biomarkers associated
with TB progression. HIV-
positive and negative factory
workers with an overall me-
dian follow-up of 3.8 years
and 6-monthly assessments.
Low CD4 and high viral
load associated with TB
incidence; successful
TB treatment does not
reduce viral load.
95 Black African
≥500 0 43 0
50 38d (34) 52 Heterosexual C/A/B
Notes.
aQuality assessed with a modified Newcastle-Ottawa scale for cohorts with A/B/C according to all/some/few criteria met in each domain.
bMean.
cInter-quartile range.
d5 mm cut-off used in tuberculin skin test.
eCut-off used in tuberculin skin test not stated.
fReference value.
gCohort number restricted to those included in TB incidence calculation.
aHR, adjusted hazard ratio; ART, antiretroviral therapy; IPT, isoniazid preventive therapy; TB, tuberculosis; RCT, randomized controlled trial; PPD, purified protein derivative; TST, tuberculin
skin test; PLHIV, people living with HIV; IDU, injecting drug users; MSM, men who have sex with men.
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Figure 2 Incidence of tuberculosis in adults living with HIV (age≥15 years) not on antiretroviral ther-
apy, by study and CD4-positive lymphocyte count. Study data reported as incidence are plotted as trian-
gles with confidence intervals; study data reported as hazard ratios are reported as dots, with confidence
intervals except for the reference category. Note: the rightmost data point for Wolday, 2003 had zero TB
cases which is not defined on a logarithmic scale—only the top of the Poisson exact confidence interval is
shown, with the bottom truncated.
Full-size DOI: 10.7717/peerj.4165/fig-2
around half of the incident TB cases reported in one study (Monge et al., 2014) were on
ART, and so we used the adjusted hazard ratio for this study (which adjusted for ART
status) in the meta-analysis. The studies analyzed as reporting TB incidence (four of seven)
contributed 868 incident TB cases during 50,045 person-years of observation. While the
background TB incidence rates varied substantially between settings, the trends in TB
incidence by CD4 count within study qualitatively supported the assumption of a linear
relation to logarithmic TB incidence (see Fig. 2). CD4 categories were not the same across
studies, and typical intervals between measurements also varied.
The studies were rated as having high comparability, since the comparison was between
subgroups of the same cohort (see Table 1). Quality around outcome measurements was
also generally good; likewise for selection of individuals (representativeness of PLHIV in
given country, ascertainment of HIV status). The funnel plot (see Appendix S1) showed 3
of the seven studies fell just outside the lower funnel boundary; formal tests of publication
bias were not used since the number of studies included was fewer than 10.
Statistical analysis
The Gelman–Rubin statistics for the MCMC chains (chains plotted in Appendix S1) were
all ≤ 1.002. The estimates of individual study log-TB incidence gradients with respect to
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Figure 3 Forest plot of the rate of increase logarithmic tuberculosis incidence with CD4-positive lym-
phocyte count in adults living with HIV (age≥15 years) not on antiretroviral therapy. Summary and
individual study measures are based on the posteriors from the hierarchical meta-analysis.
Full-size DOI: 10.7717/peerj.4165/fig-3
CD4 are shown in the forest plot (see Fig. 3) together with the summary estimate that
was 0.36 (95% credible interval (CrI [0.15–0.63]) per 100 cells/mm3 (see Appendix S1
for table). The heterogeneity measured by τ 2 was 0.048 (95% CrI [0.003–0.44]) per (100
cells/mm3)2. This corresponds to an I 2 statistic of 96%. The sensitivity analysis using a
point-estimate of incidence a factor of 10 times smaller for the data point with no TB events
yielded a log-TB incidence gradient with respect to CD4 of 0.40 (95% CrI [0.09–0.78]).
This log-TB incidence gradient is equivalent to a 1.43 (95% CrI [1.16 –1.88])-fold
increase in TB incidence risk per 100 cells per mm3 decline in CD4 count. The IRR implied
by this result as CD4 cell-count declines rises from just under 3 for those with CD4 cell
count over 500 cells per mm3 to over 25 for those with CD4 cell counts under 200 cells per
mm3 (Fig. 4).
DISCUSSION
Our systematic review and meta-analysis confirms decline in CD4 cell count among HIV-
positive adults (aged ≥15 years) not receiving ART as a strong risk factor for incident TB,
with the IRR for TB increasing exponentially as CD4 cell count declines. Our meta-analysis
of the gradient of logarithmic TB incidence with respect to CD4 count is very close to
the estimate produced previous analyses (Williams & Dye, 2003; Williams et al., 2010) but
based on a non-overlapping set of papers.
The papers included in previous analyses (Williams & Dye, 2003; Williams et al., 2010)
were captured by our review but rejected on the grounds they did not separately report
Ellis et al. (2017), PeerJ, DOI 10.7717/peerj.4165 9/15
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Figure 4 Increase in relative risk of tuberculosis incidence in adults living with HIV (age≥15 years)
not on antiretroviral therapy by CD4-positive lymphocyte count. Thick dashed lines represent 95%
credible intervals around the point estimate (thick solid line); horizontal lines represent means over de-
picted CD4 categories; dotted lines represent 95% credible intervals for these category means; the hori-
zontal dashed line represents an incidence rate ratio of 1 (no change). It is assumed that individuals have a
CD4 count of 1,000 cells/mm3 at the point of HIV infection.
Full-size DOI: 10.7717/peerj.4165/fig-4
TB incidence off ART or only measured CD4 cell count at baseline (one of our a priori
exclusion criteria). It is reassuring that our analysis reaches a very similar number from
a different body of evidence, while including more patients from sub-Saharan Africa.
However, in retrospect, since some of the studies we included had only infrequent CD4
measurement, e.g.,Collins et al. (2015) or did not report the regularity of measurement; it is
not clear that their CD4 count categories are necessarily a more robust indicator of current
CD4 count than a baseline measurement in study of short duration, e.g., Antonucci et al.
(1995) included inWilliams & Dye (2003). Another limitation of our analysis is associated
with CD4 cell count categories: these were broad and differed between studies, and for our
meta-analyses we used category mid-point.
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We did not consider children (aged under 15 years) in our analysis, who have very
different natural histories for both TB and HIV. The relationship between TB and HIV in
children is the subject of a separate systematic review and meta-analysis (Dodd et al., 2017).
It is possible that a small number of individuals may have contributed person-time at age
14 to the cohort inMonge et al. (2014).
A strength of this work is that the data included was based on the results of a systematic
review with a clearly defined a priori search strategy, which captured all relevant articles
of which we were aware. Our search did have limitations however: it restricted to articles
in English; and while it included MEDLINE, it did not include another large general
database such as Embase. The quality of studies included was generally rated as high for
our analysis, although our assessment tool did not capture shortcomings such as the timing
of CD4 measurements. There were too few studies included to formally assess evidence of
publication bias.
The prevalence ofMycobacterium tuberculosis (M.tb) infection asmeasured by tuberculin
skin test (TST) was available for a minority of studies. This is relevant because infection
with M.tb is thought to confer protection against incident disease from re-infection
in HIV-uninfected individuals (Andrews et al., 2012), and it may be that HIV increases
susceptibility to M.tb infection. The protection conferred by previous infection is often
assumed to be absent in PLHIV, but quantitative evidence is lacking due to the particular
problems of TST as a test for infection in this population (Ayubi et al., 2016). Ultimately,
this means the relationship analyzed is between CD4 count and TB incidence either from
primary progression, re-activation or re-infection. HIV and CD4 decline may impact
differently on the different routes to TB disease.
The statistical heterogeneity associated with our included studies was high. However
with few studies and only study-level covariates usually available, we were not able to
investigate potential causes of heterogeneity. These may have included differences between
populations, strains of TB orHIV, by epidemic type or transmission route, and confounding
by age or sex. BCG vaccination status was not reported, except for one study (Wolday et
al., 2003), and may itself have confounded results, either through variation in coverage or
variation in efficacy.
Despite the shortcomings discussed above, confidence in our results in increased by the
closeness to previous similar analyses, as well as with expectations from other studies not
based onTB incidence in cohorts. The average predicted IRRover all CD4 counts (∼8) is not
dissimilar to the early population estimates (Corbett et al., 2003) based on the prevalence
of HIV in TB cases. The increase in TB risk immediately following sero-conversion has
been estimated as∼2 (Sonnenberg et al., 2005), which is compatible with the average of∼2
over the CD4 category 500–1,000 cells per mm3.
It is noteworthy that many of the limitations we discuss above could be circumvented
by an individual patient meta-analysis. This would obviate the CD4 category mid-point
assumption and time since the last CD4 measurement could be used (potentially in
conjunction with imputation via models of CD4 dynamics). The effects of potential
confounders such as age, sex andHIV infection route could be considered. Other questions,
such as the impact of incident TB disease on CD4 dynamics or the relationship between
Ellis et al. (2017), PeerJ, DOI 10.7717/peerj.4165 11/15
updated CD4 cell count, time on ART, and TB incidence in PLHIV who are on ART might
also be accessible. This last question, in addition to its intrinsic interest, would also allow
individual patient models to include more detail and heterogeneity in their representations
of TB risk.
CONCLUSIONS
The high risk of TB conferred by untreated HIV infection, the large fraction of HIV
deaths associated with TB, and the still substantial numbers of PLHIV who are not on
treatment underscores the importance of HIV testing, prompt ART initiation and TB-
preventive therapy. Our analysis affirms the quantitative relationship underlying many TB
models used in epidemic projection and resource planning. Our review and analysis both
highlight the potential for an individual patient meta-analysis to improve our quantitative
understanding of the relationship between HIV infection and TB risk.
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